Copcu H Eray
From the Aesthetic, Plastic and Reconstructive Surgery, G-CAT (Gene, and Tissue) Academy, Istanbul, Turkey.
Plast Reconstr Surg Glob Open. 2024 Jul 16;12(7):e5982. doi: 10.1097/GOX.0000000000005982. eCollection 2024 Jul.
Among all regenerative applications developed in recent years, the use of exosomes has generated by far the greatest interest. Exosome products from allogeneic and xenogeneic sources are available on the market. A key challenge is controlling the effects of nonautologous exosomes. We hypothesized that combining exosomes with a patient's own extracellular matrix (ECM) can create "autologization," enabling control over their effects. This study aimed to provide the rationale and a guide for future research exploring the autologization of exosome applications using deparenchymized adipose tissue (DPAT).
DPAT adipose tissue was achieved using 1200-, 400-, and 35-micrometer blades in an ultrasharp blade system (Adinizer), and then "autologization" was achieved by combining the obtained DPAT with allogeneic exosomes. DPAT was evaluated histochemically, and exosomes were counted and analyzed with the Nanosight device.
The DPAT process using ultrasharp blades is easily performed. DPAT obtained from adipose tissue was then combined with allogenic exosomes. It has been demonstrated histopathologically that adipocytes are eliminated in deparenchymized fat tissue, and only ECM and stromal cells remain. It has also been proven that the number of exosomes is not affected by the combination.
This study introduces two novel concepts previously unknown in the literature, "deparenchymization" and "autologization," representing an innovative approach in plastic surgery and regenerative medicine. Our novel approach enriches regenerative cells while preserving critical ECM signals, overcoming the limitations of existing isolation methods. Extensive research is still needed, but autologization using DPAT ECM holds great promise for translating exosome-based treatments into practice.
在近年来开发的所有再生应用中,外泌体的应用引发了迄今为止最大的关注。市场上已有来自同种异体和异种来源的外泌体产品。一个关键挑战是控制非自体外泌体的作用。我们假设将外泌体与患者自身的细胞外基质(ECM)相结合可以实现“自体化”,从而能够控制其作用。本研究旨在为未来探索使用去实质脂肪组织(DPAT)实现外泌体应用自体化的研究提供理论依据和指导。
在超锋利刀片系统(Adinizer)中使用1200微米、400微米和35微米的刀片获得DPAT脂肪组织,然后将获得的DPAT与同种异体外泌体相结合以实现“自体化”。对DPAT进行组织化学评估,并用纳米可视分析仪对外泌体进行计数和分析。
使用超锋利刀片进行DPAT过程很容易操作。从脂肪组织获得的DPAT随后与同种异体外泌体相结合。组织病理学证明,去实质脂肪组织中的脂肪细胞被消除,仅保留ECM和基质细胞。还证明外泌体的数量不受这种结合的影响。
本研究引入了文献中先前未知的两个新概念,即“去实质化”和“自体化”,代表了整形外科和再生医学中的一种创新方法。我们的新方法在保留关键ECM信号的同时丰富了再生细胞,克服了现有分离方法的局限性。仍需要进行大量研究,但使用DPAT ECM进行自体化对于将基于外泌体的治疗转化为实际应用具有巨大潜力。